

Magle Chemoswed Q2 2023 - Progress toward transition

Redeye provides a research update following the Q2 report published by Magle yesterday. Overall, the report was in line with our expectations. However, we are encouraged by the progress made by the company during the period. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Magle Chemoswed Q2 2023 - Progress toward transition